Mental Health in Chronic and End-Stage Heart Disease

  • Yelizaveta SherEmail author


Patients with heart disease and heart failure (HF) have increased rates of depression and anxiety. Not only these psychiatric conditions cause significant distress and impaired quality of life, but research has shown that depression increases the risk of hospitalizations, worsens adherence to medication regimen, and increases the mortality in cardiac transplant recipients. While studies on pharmacological treatments for depression have been promising in patients with ischemic heart disease, so far antidepressants have not been demonstrated as effective treatments for depression in patients with HF. In addition, treatment of depression with antidepressants has not been shown to decrease mortality in cardiac patients; however, remission of depression in general has been shown to be associated with such decrease. Non-pharmacological treatments, such as therapy, exercise, and collaborative care modes are promising for better identification and reduction of mental disorder symptoms. In addition, patients with severe mental illness are at higher risk for cardiovascular mortality and are less likely to receive needed treatments. Finally, cognitive impairment is common in cardiac patients and contributes to challenges in care.


Heart disease Heart failure Depression Anxiety Cognitive impairment 


  1. 1.
    Denollet J, Sys SU, Brutsaert DL. Personality and mortality after myocardial infarction. Psychosom Med. [Comparative Study Research Support, Non-U.S. Gov’t]. 1995;57(6):582–91.Google Scholar
  2. 2.
    O’Neil A, Fisher AJ, Kibbey KJ, Jacka FN, Kotowicz MA, Williams LJ, et al. Depression is a risk factor for incident coronary heart disease in women: an 18-year longitudinal study. J Affect Disord. [Research Support, Non-U.S. Gov’t]. 2016;196:117–24.Google Scholar
  3. 3.
    Wulsin LR, Singal BM. Do depressive symptoms increase the risk for the onset of coronary disease? A systematic quantitative review. Psychosom Med. [Meta-Analysis Review]. 2003;65(2):201–10.CrossRefGoogle Scholar
  4. 4.
    Huffman JC, Adams CN, Celano CM. Collaborative care and related interventions in patients with heart disease: An update and new directions. Psychosomatics. [Review]. 2018;59(1):1–18.CrossRefGoogle Scholar
  5. 5.
    Sher Y, Lolak S, Maldonado JR. The impact of depression in heart disease. Curr Psychiatry Rep. [Review]. 2010;12(3):255–64.CrossRefGoogle Scholar
  6. 6.
    Newhouse A, Jiang W. Heart failure and depression. Heart Fail Clin. [Review]. 2014;10(2):295–304.CrossRefGoogle Scholar
  7. 7.
    Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry. [Research Support, Non-U.S. Gov’t Review]. 2003;54(3):227–40.CrossRefGoogle Scholar
  8. 8.
    Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. [Meta-Analysis]. 2006;48(8):1527–37.CrossRefGoogle Scholar
  9. 9.
    Schowalter M, Gelbrich G, Stork S, Langguth JP, Morbach C, Ertl G, et al. Generic and disease-specific health-related quality of life in patients with chronic systolic heart failure: impact of depression. Clin Res Cardiol. [Research Support, Non-U.S. Gov’t]. 2013;102(4):269–78.CrossRefGoogle Scholar
  10. 10.
    Muller-Tasch T, Peters-Klimm F, Schellberg D, Holzapfel N, Barth A, Junger J, et al. Depression is a major determinant of quality of life in patients with chronic systolic heart failure in general practice. J Card Fail. [Comparative Study Research Support, Non-U.S. Gov’t]. 2007;13(10):818–24.Google Scholar
  11. 11.
    Albert NM, Fonarow GC, Abraham WT, Gheorghiade M, Greenberg BH, Nunez E, et al. Depression and clinical outcomes in heart failure: an OPTIMIZE-HF analysis. Am J Med. [Research Support, Non-U.S. Gov’t]. 2009;122(4):366–73.CrossRefGoogle Scholar
  12. 12.
    Braunstein JB, Anderson GF, Gerstenblith G, Weller W, Niefeld M, Herbert R, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. [Research Support, Non-U.S. Gov’t]. 2003;42(7):1226–33.CrossRefGoogle Scholar
  13. 13.
    Lesman-Leegte I, van Veldhuisen DJ, Hillege HL, Moser D, Sanderman R, Jaarsma T. Depressive symptoms and outcomes in patients with heart failure: data from the COACH study. Eur J Heart Fail. [Research Support, Non-U.S. Gov’t]. 2009;11(12):1202–7.CrossRefGoogle Scholar
  14. 14.
    Moraska AR, Chamberlain AM, Shah ND, Vickers KS, Rummans TA, Dunlay SM, et al. Depression, healthcare utilization, and death in heart failure: a community study. Circ Heart Fail. [Research Support, N.I.H., Extramural]. 2013;6(3):387–94.Google Scholar
  15. 15.
    Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O’Connor CM, Adams KF, Jr., et al. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med. [Multicenter Study Research Support, N.I.H., Extramural]. 2007;167(4):367–73.Google Scholar
  16. 16.
    Palacios J, Khondoker M, Mann A, Tylee A, Hotopf M. Depression and anxiety symptom trajectories in coronary heart disease: associations with measures of disability and impact on 3-year health care costs. J Psychosom Res. 2018;104:1–8.CrossRefGoogle Scholar
  17. 17.
    Lichtman JH, Froelicher ES, Blumenthal JA, Carney RM, Doering LV, Frasure-Smith N, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation. [Meta-Analysis Review]. 2014;129(12):1350–69.CrossRefGoogle Scholar
  18. 18.
    Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J. [Meta-Analysis Research Support, Non-U.S. Gov’t]. 2006;27(23):2763–74.Google Scholar
  19. 19.
    Penninx BW, Beekman AT, Honig A, Deeg DJ, Schoevers RA, van Eijk JT, et al. Depression and cardiac mortality: results from a community-based longitudinal study. Arch Gen Psychiatry. [Research Support, Non-U.S. Gov’t]. 2001;58(3):221–7.CrossRefGoogle Scholar
  20. 20.
    Barth J, Schumacher M, Herrmann-Lingen C. Depression as a risk factor for mortality in patients with coronary heart disease: a meta-analysis. Psychosom Med. [Comparative Study Meta-Analysis]. 2004;66(6):802–13.CrossRefGoogle Scholar
  21. 21.
    Wellenius GA, Mukamal KJ, Kulshreshtha A, Asonganyi S, Mittleman MA. Depressive symptoms and the risk of atherosclerotic progression among patients with coronary artery bypass grafts. Circulation. [Comparative Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2008;117(18):2313–9.Google Scholar
  22. 22.
    Adams J, Kuchibhatla M, Christopher EJ, Alexander JD, Clary GL, Cuffe MS, et al. Association of depression and survival in patients with chronic heart failure over 12 Years. Psychosomatics. 2012;53(4):339–46. Scholar
  23. 23.
    Glassman AH, O’Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Jr., et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2002;288(6):701–9.Google Scholar
  24. 24.
    van Melle JP, de Jonge P, Honig A, Schene AH, Kuyper AM, Crijns HJ, et al. Effects of antidepressant treatment following myocardial infarction. Br J Psychiatry. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2007;190:460–6.Google Scholar
  25. 25.
    Lesperance F, Frasure-Smith N, Koszycki D, Laliberte MA, van Zyl LT, Baker B, et al. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy (CREATE) trial. JAMA. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2007;297(4):367–79.Google Scholar
  26. 26.
    Echols MR, Jiang W. Clinical trial evidence for treatment of depression in heart failure. Heart Fail Clin. [Review]. 2011;7(1):81–8.CrossRefGoogle Scholar
  27. 27.
    O’Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, et al. Safety and efficacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol. [Randomized Controlled Trial Research Support, N.I.H., Extramural]. 2010;56(9):692–9.Google Scholar
  28. 28.
    Angermann CE, Gelbrich G, Stork S, Gunold H, Edelmann F, Wachter R, et al. Effect of escitalopram on all-cause mortality and hospitalization in patients with heart failure and depression: the MOOD-HF randomized clinical trial. JAMA. [Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2016;315(24):2683–93.Google Scholar
  29. 29.
    Berkman LF, Blumenthal J, Burg M, Carney RM, Catellier D, Cowan MJ, et al. Effects of treating depression and low perceived social support on clinical events after myocardial infarction: the Enhancing Recovery in Coronary Heart Disease Patients (ENRICHD) Randomized Trial. JAMA. [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, U.S. Gov’t, P.H.S.]. 2003;289(23):3106–16.Google Scholar
  30. 30.
    Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, et al. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry. [Clinical Trial Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, U.S. Gov’t, P.H.S.]. 2005;62(7):792–8.Google Scholar
  31. 31.
    Kim JM, Bae KY, Stewart R, Jung BO, Kang HJ, Kim SW, et al. Escitalopram treatment for depressive disorder following acute coronary syndrome: a 24-week double-blind, placebo-controlled trial. J Clin Psychiatry. [Randomized Controlled Trial Research Support, Non-U.S. Gov’t]. 2015;76(1):62–8.Google Scholar
  32. 32.
    Rigotti NA, Thorndike AN, Regan S, McKool K, Pasternak RC, Chang Y, et al. Bupropion for smokers hospitalized with acute cardiovascular disease. Am J Med. [Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2006;119(12):1080–7.Google Scholar
  33. 33.
    Blumenthal JA, Sherwood A, Babyak MA, Watkins LL, Smith PJ, Hoffman BM, et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol. [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2012;60(12):1053–63.Google Scholar
  34. 34.
    Herrmann-Lingen C, Beutel ME, Bosbach A, Deter HC, Fritzsche K, Hellmich M, et al. A stepwise psychotherapy intervention for reducing risk in coronary artery disease (SPIRR-CAD): results of an observer-blinded, multicenter, randomized trial in depressed patients with coronary artery disease. Psychosom Med. [Multicenter Study Randomized Controlled Trial]. 2016;78(6):704–15.CrossRefGoogle Scholar
  35. 35.
    Freedland KE, Carney RM, Rich MW, Steinmeyer BC, Rubin EH. Cognitive behavior therapy for depression and self-care in heart failure patients: A randomized clinical trial. JAMA Intern Med. [Randomized Controlled Trial]. 2015;175(11):1773–82.CrossRefGoogle Scholar
  36. 36.
    Wells A, McNicol K, Reeves D, Salmon P, Davies L, Heagerty A, et al. Improving the effectiveness of psychological interventions for depression and anxiety in the cardiac rehabilitation pathway using group-based metacognitive therapy (PATHWAY Group MCT): study protocol for a randomised controlled trial. Trials. 2018;19(1):215.CrossRefGoogle Scholar
  37. 37.
    Blumenthal JA, Babyak MA, O’Connor C, Keteyian S, Landzberg J, Howlett J, et al. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA. [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, N.I.H., Extramural]. 2012;308(5):465–74.Google Scholar
  38. 38.
    Carney RM, Freedland KE, Steinmeyer BC, Rubin EH, Rich MW. Residual symptoms following treatment for depression in patients with coronary heart disease. Psychosom Med. 2018;80(4): 385–92Google Scholar
  39. 39.
    Tully PJ, Baumeister H. Collaborative care for comorbid depression and coronary heart disease: a systematic review and meta-analysis of randomised controlled trials. BMJ Open. [Meta-Analysis Research Support, Non-U.S. Gov’t Review]. 2015;5(12):e009128.Google Scholar
  40. 40.
    Beach SR, Celano CM, Noseworthy PA, Januzzi JL, Huffman JC. QTc prolongation, torsades de pointes, and psychotropic medications. Psychosomatics. [Review]. 2013;54(1):1–13.CrossRefGoogle Scholar
  41. 41.
    Castro VM, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, et al. QT interval and antidepressant use: a cross sectional study of electronic health records. BMJ. [Comparative Study Research Support, N.I.H., Extramural]. 2013;346:f288.Google Scholar
  42. 42.
    Eckersley MJ, Sepehripour AH, Casula R, Punjabi P, Athanasiou T. Do selective serotonin reuptake inhibitors increase the risk of bleeding or mortality following coronary artery bypass graft surgery? A meta-analysis of observational studies. Perfusion. 2018:267659118765933.Google Scholar
  43. 43.
    Ziegelstein RC, Parakh K, Sakhuja A, Bhat U. Platelet function in patients with major depression. Intern Med J. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. 2009;39(1):38–43.CrossRefGoogle Scholar
  44. 44.
    Shapiro PA. Cardiovascular disorders. In: Ferrando SJ, Levenson JL, Owen JA, editors. Clinical manual of psychopharmacology in medically ill. Washington, DC/New York: American Psychiatric Publishing; 2010. p. 181–212.Google Scholar
  45. 45.
    Tully PJ, Cosh SM, Baumeister H. The anxious heart in whose mind? A systematic review and meta-regression of factors associated with anxiety disorder diagnosis, treatment and morbidity risk in coronary heart disease. J Psychosom Res. [Research Support, Non-U.S. Gov’t Review]. 2014;77(6):439–48.CrossRefGoogle Scholar
  46. 46.
    Roest AM, Martens EJ, de Jonge P, Denollet J. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol. [Meta-Analysis Research Support, Non-U.S. Gov’t]. 2010;56(1):38–46.Google Scholar
  47. 47.
    Edmondson D, Kronish IM, Shaffer JA, Falzon L, Burg MM. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. Am Heart J. [Meta-Analysis Review]. 2013;166(5):806–14.CrossRefGoogle Scholar
  48. 48.
    Tully PJ, Turnbull DA, Beltrame J, Horowitz J, Cosh S, Baumeister H, et al. Panic disorder and incident coronary heart disease: a systematic review and meta-regression in 1131612 persons and 58111 cardiac events. Psychol Med. [Meta-Analysis Research Support, Non-U.S. Gov’t Review]. 2015;45(14):2909–20.Google Scholar
  49. 49.
    Easton K, Coventry P, Lovell K, Carter LA, Deaton C. Prevalence and measurement of anxiety in samples of patients with heart failure: meta-analysis. J Cardiovasc Nurs. [Meta-Analysis]. 2016;31(4):367–79.CrossRefGoogle Scholar
  50. 50.
    Dekker RL, Lennie TA, Doering LV, Chung ML, Wu JR, Moser DK. Coexisting anxiety and depressive symptoms in patients with heart failure. Eur J Cardiovasc Nurs. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t]. 2014;13(2):168–76.Google Scholar
  51. 51.
    Vongmany J, Hickman LD, Lewis J, Newton PJ, Phillips JL. Anxiety in chronic heart failure and the risk of increased hospitalisations and mortality: a systematic review. Eur J Cardiovasc Nurs. [Review]. 2016;15(7):478–85.CrossRefGoogle Scholar
  52. 52.
    Celano CM, Millstein RA, Bedoya CA, Healy BC, Roest AM, Huffman JC. Association between anxiety and mortality in patients with coronary artery disease: a meta-analysis. Am Heart J. [Meta-Analysis Review]. 2015;170(6):1105–15.CrossRefGoogle Scholar
  53. 53.
    Newcomer JW, Hennekens CH. Severe mental illness and risk of cardiovascular disease. JAMA. [Research Support, N.I.H., Extramural]. 2007;298(15):1794–6.CrossRefGoogle Scholar
  54. 54.
    Mangurian C, Newcomer JW, Modlin C, Schillinger D. Diabetes and cardiovascular care among people with severe mental illness: a literature review. J Gen. Intern Med. [Case Reports Review]. 2016;31(9):1083–91.CrossRefGoogle Scholar
  55. 55.
    Le Melle SM, Entelis C. Heart transplant in a young man with schizophrenia. Am J Psychiatry. [Case Reports Clinical Conference]. 2005;162(3):453–7.Google Scholar
  56. 56.
    Kugathasan P, Laursen TM, Grontved S, Jensen SE, Aagaard J, Nielsen RE. Increased long-term mortality after myocardial infarction in patients with schizophrenia. Schizophr Res. 2018;199:103–8.CrossRefGoogle Scholar
  57. 57.
    Zimbrean P, Emre S. Patients with psychotic disorders in solid-organ transplant. Prog Transplant. 2015;25(4):289–96.CrossRefGoogle Scholar
  58. 58.
    Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. [Comparative Study Meta-Analysis Review]. 2013;382(9896):951–62.CrossRefGoogle Scholar
  59. 59.
    Cannon JA, Moffitt P, Perez-Moreno AC, Walters MR, Broomfield NM, McMurray JJV, et al. Cognitive impairment and heart failure: systematic review and meta-analysis. J Card Fail. [Review]. 2017;23(6):464–75.CrossRefGoogle Scholar
  60. 60.
    Kitt J, Irons R, Al-Obaidi M, Missouris C. A case of donepezil-related torsades de pointes. BMJ Case Rep. [Case Reports]. 2015;2015.Google Scholar
  61. 61.
    Takaya T, Okamoto M, Yodoi K, Hata K, Kijima Y, Nakajima H, et al. Torsades de pointes with QT prolongation related to donepezil use. J Cardiol. [Case Reports]. 2009;54(3):507–11.CrossRefGoogle Scholar
  62. 62.
    Freedenberg V, Thomas SA, Friedmann E. Anxiety and depression in implanted cardioverter-defibrillator recipients and heart failure: a review. Heart Fail Clin. [Review]. 2011;7(1):59–68.CrossRefGoogle Scholar
  63. 63.
    Thomas SA, Friedmann E, Kao CW, Inguito P, Metcalf M, Kelley FJ, et al. Quality of life and psychological status of patients with implantable cardioverter defibrillators. Am J Crit Care. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t Review]. 2006;15(4):389–98.Google Scholar
  64. 64.
    Habibovic M, van den Broek KC, Alings M, Van der Voort PH, Denollet J. Posttraumatic stress 18 months following cardioverter defibrillator implantation: shocks, anxiety, and personality. Health Psychol. 2012;31(2):186–93.CrossRefGoogle Scholar
  65. 65.
    Kobe J, Hucklenbroich K, Geisendorfer N, Bettin M, Frommeyer G, Reinke F, et al. Posttraumatic stress and quality of life with the totally subcutaneous compared to conventional cardioverter-defibrillator systems. Clin Res Cardiol. [Controlled Clinical Trial]. 2017;106(5):317–21.CrossRefGoogle Scholar
  66. 66.
    Bidwell JT, Lyons KS, Mudd JO, Gelow JM, Chien CV, Hiatt SO, et al. Quality of life, depression, and anxiety in ventricular assist device therapy: longitudinal outcomes for patients and family caregivers. J Cardiovasc Nurs. 2017;32(5):455–63.CrossRefGoogle Scholar
  67. 67.
    Yost G, Bhat G, Mahoney E, Tatooles A. Reduced anxiety and depression in patients with advanced heart failure after left ventricular assist device implantation. Psychosomatics. 2017;58(4):406–14.CrossRefGoogle Scholar
  68. 68.
    Reynard AK, Butler RS, McKee MG, Starling RC, Gorodeski EZ. Frequency of depression and anxiety before and after insertion of a continuous flow left ventricular assist device. Am J Cardiol. [Research Support, Non-U.S. Gov’t]. 2014;114(3):433–40.CrossRefGoogle Scholar
  69. 69.
    Balliet WE, Madan A, Craig ML, Serber ER, Borckardt JJ, Pelic C, et al. A ventricular assist device recipient and suicidality: multidisciplinary collaboration with a psychiatrically distressed patient. J Cardiovasc Nurs. [Case Reports]. 2017;32(2):135–9.CrossRefGoogle Scholar
  70. 70.
    Tigges-Limmer K, Schonbrodt M, Roefe D, Arusoglu L, Morshuis M, Gummert JF. Suicide after ventricular assist device implantation. J. Heart Lung Transplant. [Case Reports]. 2010;29(6):692–4.CrossRefGoogle Scholar
  71. 71.
    Brouwers C, Denollet J, Caliskan K, de Jonge N, Constantinescu A, Young Q, et al. Psychological distress in patients with a left ventricular assist device and their partners: an exploratory study. Eur J Cardiovasc Nurs. [Comparative Study Multicenter Study Observational Study Research Support, Non-U.S. Gov’t]. 2015;14(1):53–62.Google Scholar
  72. 72.
    Bhat G, Yost G, Mahoney E. Cognitive function and left ventricular assist device implantation. J Heart Lung Transplant. 2015;34(11):1398–405.CrossRefGoogle Scholar
  73. 73.
    Petrucci RJ, Wright S, Naka Y, Idrissi KA, Russell SD, Dordunoo D, et al. Neurocognitive assessments in advanced heart failure patients receiving continuous-flow left ventricular assist devices. J Heart Lung Transplant. [Clinical Trial]. 2009;28(6):542–9.CrossRefGoogle Scholar
  74. 74.
    Cho SM, Moazami N, Frontera JA. Stroke and intracranial hemorrhage in HeartMate II and HeartWare left ventricular assist devices: a systematic review. Neurocrit Care. [Review]. 2017;27(1):17–25.CrossRefGoogle Scholar
  75. 75.
    Yuppa DP, Nichols S. Amiodarone-induced delirium in advanced cancer: a case report. Psychosomatics. [Case Reports]. 2013;54(3):294–6.CrossRefGoogle Scholar
  76. 76.
    Barry JJ, Franklin K. Amiodarone-induced delirium. Am J Psychiatry. [Case Reports Letter]. 1999;156(7):1119.Google Scholar
  77. 77.
    Keller S, Frishman WH. Neuropsychiatric effects of cardiovascular drug therapy. Cardiol Rev. [Review]. 2003;11(2):73–93.CrossRefGoogle Scholar
  78. 78.
    Piltz JR, Wertenbaker C, Lance SE, Slamovits T, Leeper HF. Digoxin toxicity. Recognizing the varied visual presentations. J Clin Neuroophthalmol. [Case Reports]. 1993;13(4):275–80.Google Scholar
  79. 79.
    Renard D, Rubli E, Voide N, Borruat FX, Rothuizen LE. Spectrum of digoxin-induced ocular toxicity: a case report and literature review. BMC Res Notes. [Case Reports Review]. 2015;8:368.Google Scholar
  80. 80.
    Maldonado JR, Sher Y, Lolak S, Swendsen H, Skibola D, Neri E, et al. The Stanford Integrated Psychosocial Assessment for Transplantation: a prospective study of medical and psychosocial outcomes. Psychosom Med. [Research Support, Non-U.S. Gov’t]. 2015;77(9):1018–30.CrossRefGoogle Scholar
  81. 81.
    Owen JE, Bonds CL, Wellisch DK. Psychiatric evaluations of heart transplant candidates: predicting post-transplant hospitalizations, rejection episodes, and survival. Psychosomatics. 2006;47(3):213–22.CrossRefGoogle Scholar
  82. 82.
    Dew MA, Rosenberger EM, Myaskovsky L, DiMartini AF, DeVito Dabbs AJ, Posluszny DM, et al. Depression and anxiety as risk factors for morbidity and mortality after organ transplantation: a systematic review and meta-analysis. Transplantation. 2015;100(5):988–1003.CrossRefGoogle Scholar
  83. 83.
    Delibasic M, Mohamedali B, Dobrilovic N, Raman J. Pre-transplant depression as a predictor of adherence and morbidities after orthotopic heart transplantation. J Cardiothorac Surg. 2017;12(1):62.CrossRefGoogle Scholar
  84. 84.
    Vandenbogaart E, Doering L, Chen B, Saltzman A, Chaker T, Creaser JW, et al. Evaluation of the SIPAT instrument to assess psychosocial risk in heart transplant candidates: a retrospective single center study. Heart Lung. [Evaluation Studies]. 2017;46(4):273–9.CrossRefGoogle Scholar
  85. 85.
    Flynn K, Daiches A, Malpus Z, Yonan N, Sanchez M. ‘A post-transplant person’: narratives of heart or lung transplantation and intensive care unit delirium. Health. 2014;18(4):352–68.CrossRefGoogle Scholar
  86. 86.
    Zipfel S, Lowe B, Paschke T, Immel B, Lange R, Zimmermann R, et al. Psychological distress in patients awaiting heart transplantation. J Psychosom Res. [Research Support, Non-U.S. Gov’t]. 1998;45(5):465–70.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of Psychiatry and Behavioral SciencesStanford University School of MedicineStanfordUSA

Personalised recommendations